Alnylam Pharmaceuticals, Inc. (0HD2.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 02:53PM BST
| Previous close | 155.22 |
| Open | 152.13 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 151.57 - 152.13 |
| 52-week range | 143.66 - 217.98 |
| Volume | |
| Avg. volume | 1,441 |
| Market cap | 174.119M |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) just released its latest first-quarter results and things are looking...
- Insider Monkey
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75. ALNY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
- Zacks
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
© 2024 Yahoo. All rights reserved.